

CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015 (Expressed in Canadian Dollars)

Table of Contents

Independent Auditor's Report	4
Consolidated Statements of Financial Position	5
Consolidated Statements of Operations and Comprehensive Income (Loss)	6
Consolidated Statements of Changes in Shareholders' Equity	7
Consolidated Statements of Cash Flows	8
Notes to Consolidated Financial Statements:	
Note 1 – General Information	9
Note 2 – Significant Accounting Policies	9
Note 3 – Critical Accounting Estimates and Judgments	21
Note 4 – Acquisition of International Datacasting Corporation	23
Note 5 – Financial Risk and Capital Management	25
Note 6 – Inventories	29
Note 7 – Notes Receivable	29
Note 8 – Financial Instruments.	30
Note 9 – Derivative Financial Instrument	32
Note 10 – Equipment	33
Note 11 – Intangible Assets	33
Note 12 – Borrowings	33
Note 13 – Provisions	34
Note 14 – Loan Payable	35
Note 15 – Repayable Government Contribution	35
Note 16 – Shareholders' Equity	36
Note 17 – Earnings (Loss) Per Share	37
Note 18 – Research and Development Expense	38
Note 19 – Finance Income and Finance Costs	38
Note 20 – Income Taxes	39
Note 21 – Segmented Information	40

Table of Contents

Notes to Consolidated Financial Statements: (continued)

Note 22– Supplemental Cash Flow & Other Disclosures	. 41
Note 23 – Related Party Transactions	. 42
Note 24 – Operating Expenditures	. 45
Note 25 – Commitments and Contingent Liabilities	. 45
Note 26 – Subsequent Events	. 46



Collins Barrow HMA LLP

Suite 701 - 330 Portage Avenue Winnipeg, MB R3C 0C4

T: 204.989.2229 F: 204.944.9923 TF: 1.866.730.4777 www.collinsbarrow.com

INDEPENDENT AUDITORS' REPORT

To The Shareholders Novra Technologies Inc.

We have audited the accompanying consolidated financial statements of Novra Technologies Inc., which comprise the consolidated statements of financial position as at December 31, 2016 and 2015, and the consolidated statements of operations and comprehensive income (loss), changes in shareholders' equity and cash flows for the years ended December 31, 2016 and 2015, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of Novra Technologies Inc. as at December 31, 2016 and 2015, and its consolidated financial performance and its consolidated cash flows for the years ended December 31, 2016 and 2015 in accordance with International Financial Reporting Standards.

Winnipeg, Manitoba May 1, 2017 Collins Bonow HMA CLP
Chartered Professional Accountants



NOVRA TECHNOLOGIES INC. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Canadian dollars)

	NOTES	December 31, 2016	December 31, 2015
ASSETS			
Current Assets			
Cash		\$ 1,264,594	\$ 577,132
Restricted non-redeemable GIC's	12	200,000	-
Trade and other receivables	5	2,803,960	845,338
Inventories	6	2,158,549	531,255
Notes receivable	7	134,270	138,475
Prepayments		498,695	7,062
Current tax assets		3,835	-
Derivative financial instrument	9	32,225	55,281
Total Current Assets		7,096,128	2,154,543
Non-Current Assets			
Restricted non-redeemable GIC's	12	-	200,000
Equipment	10	202,531	25,937
Intangible assets	4, 11	770,324	-
Total Non-Current Assets		972,855	225,937
TOTAL ASSETS		\$ 8,068,983	\$ 2,380,480
LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities			
Trade and other payables		\$ 634,037	\$ 26,992
Accrued liabilities		752,577	248,965
Borrowings	12	2,129,892	555,000
Loan payable - current portion	14	104,123	99,575
Customer deposits		118,519	-
Deferred revenue - current portion		1,193,623	24,950
Provisions	13	56,035	24,000
Advances from related parties	23	371,110	386,636
Promissory notes from related party - current portion	23	531,499	253,406
Total Current Liabilities		5,891,415	1,595,524
Non-Current Liabilities			
Deferred revenue		108,933	_
Loan payable	14	273,023	377,147
Promissory notes from related party	23	640,569	577,147
Convertible note from related party	23	284,617	
Total Non-Current Liabilities	15	64,296 1,371,438	377,147
TOTAL LIABILITIES		7,262,853	1,972,671
Shareholders' Equity			
Share capital	16	6,778,066	6,056,729
Contributed surplus	16	472,654	-
Accumulated deficit	10	(6,444,590)	(5,648,920)
TOTAL SHAREHOLDERS' EQUITY		806,130	407,809
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		\$ 8,068,983	\$ 2,380,480
TOTAL LIABILITIES AND SHAREHOLDERS EQUIT		Ψ 0,000,363	ψ 2,300,400

See Note 25 "Commitments and Contingent Liabilities" and Note 26 "Subsequent Events"

The accompanying notes are an integral part of these Consolidated Financial Statements

NOVRA TECHNOLOGIES INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Canadian dollars, except share data)

	Ye	ars Ended I	December 31		
	NOTES		2016		2015
REVENUE	21	\$	5,042,548	\$:	2,712,671
COST OF REVENUE			2,873,260		1,779,320
GROSS PROFIT			2,169,288		933,351
OPERATING EXPENSES	2, 24				
General and administrative			917,034		199,447
Sales and marketing			592,324		112,646
Research and development, net	18		1,256,108		449,933
Total operating expenses			2,765,466		762,026
OPERATING INCOME (LOSS)			(596,178)		171,325
Other Income (Expenses)	2				
Foreign exchange gain (loss)	5		(28,336)		250,684
Loss on disposal of equipment	10		(11,760)		-
Finance income	19 (a)		7,269		6,869
Finance costs	19 (b)		(143,619)		(56,149)
Unrealized loss on options	9		(23,056)		(11,299)
INCOME (LOSS) BEFORE INCOME TAXES			(795,680)		361,430
Income tax recovery (expense)	20		10		-
NET AND COMPREHENSIVE INCOME (LOSS)		\$	(795,670)	\$	361,430
EARNINGS (LOSS) PER SHARE:	17				
Basic	• • • • • • • • • • • • • • • • • • • •	\$	(0.03)	\$	0.02
Diluted		\$	(0.03)	\$	0.02
Weighted average number of shares outstanding - basic			2,387,993		
Weighted average number of shares outstanding - diluted		:	26,043,383	2	2,387,993

The accompanying notes are an integral part of these Consolidated Financial Statements

NOVRA TECHNOLOGIES INC. CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(Canadian dollars, except share data)

	NOTES	Number of Common Shares	(Common Shares	_	ontributed Surplus	Ac	ccumulated Deficit	SI	Total nareholders' Equity
At January 1, 2016		22,387,993	\$	6,056,729	\$	-	\$	(5,648,920)	\$	407,809
Net loss for the year		-		-		-		(795,670)		(795,670)
Issuance of warrants	16	100		12		454,873		-		454,885
Issuance of convertible note	23	-		-		17,781		-		17,781
Issuance of common shares, net	4,16	6,689,342		721,325		•		-		721,325
At December 31, 2016		29,077,435	\$	6,778,066	\$	472,654	\$	(6,444,590)	\$	806,130

	NOTES	Number of Common Shares	(Common Shares	 ontributed Surplus	Ac	cumulated Deficit	Sh	Total areholders' Equity
At January 1, 2015		22,387,993	\$	6,056,729	\$ -	\$	(6,010,350)	\$	46,379
Net income for the year		-		-	-		361,430		361,430
At December 31, 2015		22,387,993	\$	6,056,729	\$ -	\$	(5,648,920)	\$	407,809

The accompanying notes are an integral part of these Consolidated Financial Statements

NOVRA TECHNOLOGIES INC. CONSOLIDATED STATEMENTS OF CASH FLOWS

(Canadian dollars)

	Years Ended Dece						
	NOTES	2016	2015				
OPERATING ACTIVITIES							
Net income (loss)		\$ (795,670)	\$ 361,430				
,		ψ (100,010)	Ψ 301,430				
Add items not requiring an outlay of cash:	40 44	406.042	5.007				
Amortization of equipment and intangible assets	10, 11 10	196,943 11,760	5,907				
Loss on disposal of equipment	6	80,666	10.607				
Inventory impairment charge	9	23,056	18,687				
Unrealized loss on options Unrealized loss on forward currency contracts	9	23,030	11,298 33,702				
Finance costs	19 (b)	143,619	56,149				
	22	•					
Changes in non-cash working capital items	22	(1,265,659)	(142,020)				
Finance costs paid		(95,195)	(54,410)				
Net cash provided by (applied to) operating activities		(1,700,480)	290,743				
INVESTING ACTIVITIES							
Purchase of IDC, net of assumed cash	4	(50,882)	-				
Purchase of equipment	10	(72,926)	(7,127)				
Net cash applied to investing activities		(123,808)	(7,127)				
FINANCING ACTIVITIES							
Repayments on borrowings		(1,719,010)	(995,000)				
Proceeds from borrowings		3,273,682	820,000				
Proceeds from promissory notes	23	1,062,888	-				
Repayments on promissory notes	12	(45,035)	-				
Repayments on long-term debt		(120,000)	(120,000)				
Proceeds from repayable government contribution	15	64,296	-				
Foreign exchange loss on financing activities		(5,071)	-				
Net cash provided by (applied to) financing activities		2,511,750	(295,000)				
Net increase (decrease) in cash		687,462	(11,384)				
Cash and cash equivalents, beginning of year		577,132	588,516				
Cash and Cash equivalents, beginning of year		5.1,102	333,310				
CASH AND CASH EQUIVALENTS, end of year		\$ 1,264,594	\$ 577,132				

The accompanying notes are an integral part of these Consolidated Financial Statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

1. General Information

Novra Technologies Inc. ("Novra") is incorporated under the Canada Business Corporations Act and its corporate office and principal place of business is 900-330 St. Mary Avenue, Winnipeg, Manitoba, Canada R3C 3Z5. Novra is a publicly traded company on the TSX Venture Exchange ("TSX-V") under the symbol NVI.

Novra has been in the satellite data distribution business since 2000. During 2016, Novra significantly expanded its product portfolio and global footprint with the acquisition of International Datacasting Corporation and its wholly-owned U.S. subsidiary (collectively referred as "IDC"), a long-time leader in the same sector (see Note 4). Novra offers a comprehensive product portfolio including hardware, software, and services. In addition to its core video, radio, and data products, areas of expertise and added value include: encryption and cybersecurity, next-generation hybrid networks (satellite/terrestrial/cloud), and efficient bandwidth utilization.

In these Consolidated Financial Statements, "Novra", "Company", "we", "us", or "our" refers to Novra Technologies Inc. and its wholly-owned subsidiaries.

On May 1, 2017, the Board of Directors authorized the Consolidated Financial Statements for issue.

2. Significant Accounting Policies

The significant accounting policies used in the preparation of these Consolidated Financial Statements are summarized below. These policies have been consistently applied to all years presented, unless otherwise noted.

Basis of Presentation

The Consolidated Financial Statements of Novra are expressed in Canadian dollars and have been prepared in accordance with International Financial Reporting Standards ("IFRS") and IFRS Interpretations Committee (IFRS IC) interpretations applicable to companies reporting under IFRS, as issued by the International Accounting Standards Board ("IASB"). We have prepared the Consolidated Financial Statements under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.

We have made certain reclassifications to prior period amounts to conform to the current period presentation for expenses. Amortization and facility costs, which were once part of general and administrative expenses, have been allocated across all expense functions, including cost of revenue. Expenses which were separately presented including corporate and investor relations, director fees, and bad debts are now included as part of general and administrative expenses. Interest expense on long-term debt has been segregated from general and administrative expenses, and is now presented separately in the Consolidated Statements of Operations and Comprehensive Loss. We have also changed the presentation of the Consolidated Statements of Cash Flows by using the indirect method rather than the direct method.

The tabular disclosures herein are presented in thousands, except for share data.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

Use of Estimates

In preparing these Consolidated Financial Statements, management has made judgments, estimates, assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. For areas involving a higher degree of management judgment or complexity, or areas where assumptions and estimates are significant to the Consolidated Financial Statements, refer to Note 3.

Consolidation

These Consolidated Financial Statements consolidate the accounts of Novra Technologies Inc. and its wholly-owned subsidiaries. Subsidiaries are all entities over which we have control. We control an entity when we are exposed, or have rights, to variable returns from our involvement with the entity and have the ability to affect those returns through our power over the entity. We have power over an entity when we have existing rights that give us the current ability to direct the activities that most significantly affect the entity's returns (relevant activities). Power may be determined on the basis of voting rights or, in the case of structured entities, other contractual arrangements. We consolidate all subsidiaries from the date we obtain control and cease consolidation when an entity is no longer controlled by us. All transactions and balances from subsidiaries have been eliminated upon consolidation.

Business Combinations

We apply the acquisition method in accounting for business combinations. We measure goodwill as the difference between the fair value of the consideration transferred, including the recognized amount of any non-controlling interest in the acquiree, and the net recognized amount (generally fair value) of the identifiable assets acquired and liabilities assumed, all measured as of the acquisition date.

Consideration transferred includes the fair value of the assets transferred (including cash), liabilities incurred by the Company on behalf of the acquiree, and equity interests issued by the Company. Consideration transferred also includes the fair value of any contingent consideration.

Transaction costs that Novra incurs in connection with a business combination, such as finders' fees, legal fees, due diligence fees, and other professional and consulting fees, are expensed in the period as incurred.

Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker ("CODM"). This CODM is responsible for allocating resources and assessing performance of the operating segments. Novra's CODM is the President and Chief Executive Officer ("CEO").

Foreign currency translation

a) Functional and presentation currency

Items included in the financial statements of each consolidated entity in the Novra group of companies are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). Management has determined the Canadian dollar to be the functional currency of the Parent company as well as its subsidiaries.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Income and expense items are translated at the average exchange rates for the period, unless foreign exchange rates fluctuated significantly during the period, in which case, the exchange rates at the dates of the transactions are used. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at periodend exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized as foreign exchange gains (losses) in the Consolidated Statements of Operations and Comprehensive Loss.

Financial Instruments

a) Financial assets

We classify Novra's financial assets in the following categories: at fair value through profit or loss, loans and receivables, and available for sale. We determine the classification of Novra's financial assets at initial recognition, depending on the purpose for which the financial assets were acquired.

i) Financial assets at fair value through profit or loss

A financial asset is classified in this category if acquired principally for the purpose of selling in the short term i.e. held for trading purposes. It also includes derivative financial instruments for trading not designated as hedges under IFRS. Financial assets in this category are recognized initially and subsequently at fair value. Initial transaction costs and the subsequent change in fair value are recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss).

Assets in this category are classified as current assets if expected to be settled within 12 months, otherwise they are classified as non-current.

ii) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Financial assets under this category includes cash as well as trade and other receivables, and notes receivable. These are initially recognized at the amount expected to be received, less, when material, a discount to reduce the loans and receivables to fair value. Subsequently, these assets are measured at amortized cost using the effective interest method, net any impairment provision.

Assets in this category are included as current assets if maturities are less than 12 months; otherwise they are classified as non-current.

iii) Available-for-sale financial assets

Available-for-sale financial assets are non-derivatives that are either designated in this category or not classified in any of the other categories. Purchases and sales of these financial assets are recognized on the trade-date i.e. the date on which Novra commits to the purchase or to sell the assets. These assets are measured at fair value plus transaction costs at inception and remeasured at each reporting period with the change in

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

fair value (including the effect of changes in foreign exchange rates) recognized in accumulated other comprehensive income within shareholders' equity. Interest and dividend income on these assets are recognized when earned and included in net earnings. When securities classified as available-for-sale are sold or impaired, the accumulated fair value adjustments recognized in equity are reclassified to gains (losses) from investment securities in the Consolidated Statements of Operations and Comprehensive Income (Loss).

Assets in this category are included as non-current assets unless the investment matures or management intends to dispose of it within 12 months of the end of the reporting period.

b) Impairment of financial assets

At each reporting date, management assesses whether there is objective evidence that a financial asset is impaired. Evidence of impairment may include indications that the debtors are experiencing significant financial difficulty, default or delinquency in payment, the probability that they will enter bankruptcy or other financial reorganization, and where observable data indicates that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults. If such evidence exists, we recognize an impairment loss, as follows:

i) Financial assets carried at amortized cost

The loss is the difference between the amortized cost of the financial asset and the present value of the estimated future cash flows, discounted using the instrument's original effective interest rate. The carrying amount of the financial asset is reduced by this amount either directly or indirectly through the use of an allowance account.

Impairment losses on financial assets carried at amortized cost are reversed in subsequent periods if the amount of the loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized.

ii) Available-for-sale financial assets

The impairment loss is the difference between the original cost of the asset and its fair value at the measurement date, less any impairment losses previously recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss). This amount represents the cumulative loss in accumulated other comprehensive loss that is reclassified to net loss.

Impairment losses on available-for-sale equity instruments are not reversed.

c) Derivative financial instruments and hedging activities

Derivatives are recognized at fair value on the date Novra enters into the derivative contract and are subsequently re-measured at their fair value. The method of recognizing the resulting gain or loss depends on whether the derivative is designated as a hedging instrument, and if so, the nature of the item being hedged.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

In 2016 and 2015, Novra did not designate any derivatives as a hedging instrument for achieving hedge accounting as defined under IFRS. As such, the change in fair value of a non-designated derivative is recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss).

The fair value of a non-designated derivative is classified as current other assets or accrued liabilities when the contract's maturity is less than 12 months; otherwise it is presented as non-current.

d) Fair value measurement

Fair value is defined as the price to sell an asset or transfer a liability (i.e. the "exit price") in an orderly transaction between market participants. Management uses a fair value hierarchy that gives the highest priority to quoted prices in active markets and the lowest priority to unobservable data. The fair value hierarchy is broken down into the following three levels:

Level 1: Fair value based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Fair value based on quoted prices in active markets for similar assets or liabilities, quoted prices for identical assets or liabilities in inactive markets, or for which significant inputs are observable (e.g. interest rates, yield curves, etc.) or can be corroborated by observable market data.

Level 3: Fair value based on inputs that are unobservable and significant to the overall fair value measurement. The unobservable inputs reflect significant management judgments about assumptions that market participants might use.

e) Financial liabilities at amortized cost

Financial liabilities at amortized cost include trade and other payables, accrued liabilities, borrowings customer deposits, loan payable, advances from related parties and promissory notes from related party. These are initially recognized at the amount required to be paid, less a discount to reduce the payables to fair value.

Financial liabilities are classified as current liabilities if payment is due within twelve months. Otherwise, they are presented as non-current liabilities.

Cash

Cash includes petty cash and unrestricted cash balances held at two high credit-quality financial institutions.

Trade and Other Receivables

Trade receivables are stated at the amounts billed to customers under normal trade, less an allowance for doubtful accounts. At each reporting date, management adjusts the allowance for doubtful accounts based upon a review of: the aging of outstanding customer balances, historical default rates, customer credit worthiness and changes in customer payment to evaluate collectability of Novra's trade and other receivable balances.

Other receivables include unbilled revenue, harmonized and goods sales tax recoverable, and accrued investment tax credits.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

Inventories

Novra's inventories consist of parts and supplies, work in progress ("WIP"), and finished goods. Inventories are measured at the lower of cost and net realizable value, with cost being determined using the weighted average cost method. The cost of WIP and finished goods include the cost of raw materials, direct labor, and manufacturing overhead. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.

At each reporting period, management estimates the provision for obsolete and slow-moving inventory which may be reversed in subsequent periods, should the value subsequently be recovered.

Prepayments

Prepayments include short-term prepaid expenses and prepayments related to materials, insurance premiums, third party software licenses, and other deposits required in the normal course of business which are less than one year.

Equipment

Equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses. Prior to June 16, 2016, depreciation on equipment was calculated as follows:

- Machinery, equipment, furniture and fixtures: 20% declining balance method
- Computer equipment: 30% declining balance method

Post June 15, 2016, following the IDC acquisition (see Note 4), we modified Novra's depreciation methodology from declining balance to straight-line depreciation to be in line with IDC's depreciation policy, which in management's opinion better reflects the estimated pattern of consumption of the future economic benefits of the equipment. This change did not have a significant impact on Novra's Consolidated Financial Statements.

Management has established the following estimated useful lives:

- Computers, peripherals and software: 3 years
- Demo and testing equipment: 3 5 years
- Furniture and fixtures: 5 10 years

The estimated useful lives, residual values, and depreciation methods are reviewed annually, with the effect of any changes in estimate accounted for prospectively.

We capitalize the cost associated with substantive betterments or improvements to equipment that significantly add to the productive capacity or extend the useful life of an asset. All other repair and maintenance costs are recognized as expenses.

Intangible Assets

Intangible assets with finite lives are measured at cost less accumulated amortization and any accumulated impairment losses. We amortized intangible assets on a straight-line basis over their estimated useful lives and are subject to impairment test as described in the Impairment of Non-Financial Assets policy.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

In connection with the acquisition of IDC, management has established an estimated useful life of 3 years for the acquired technology assets from IDC.

Useful lives, residual values and amortization methods for intangible assets with finite useful lives are reviewed at least annually. Indefinite life intangible assets are measured at cost less any accumulated impairment losses. These intangible assets are tested for impairment on an annual basis or more frequently if there are indicators that intangible assets may be impaired as described below.

Impairment of Non-Financial Assets

At each balance sheet date, management reviews the carrying amounts of Novra's non-financial assets, other than inventories and deferred tax assets, to determine whether there is any indication of impairment. If any such indication exists, the asset is then tested for impairment by comparing its recoverable amount to its carrying value.

For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of cash inflows of other assets or groups of assets. This grouping is referred to as a cash generating unit ("CGU").

The recoverable amount of a CGU or CGU grouping is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows from the CGU or CGU grouping, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU or CGU grouping. The fair value less costs to sell is based on the best information available to reflect the amount that could be obtained from the disposal of the CGU or CGU grouping in an arm's length transaction between knowledgeable and willing parties, net of estimates of the costs of disposal.

We recognize an impairment charge to operating income if the carrying amount of a CGU or CGU grouping exceeds its recoverable amount. For asset impairments, the impairment charge reduces the carrying amounts of the non-financial assets in the CGU on a pro-rata basis. Prior impairments of non-financial assets are reviewed for possible reversal at each reporting date.

Trade and Other Payables

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Other payables include corporate credit cards and harmonized and good sales tax payable. We classify trade and other payables as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

Borrowings

Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in earnings over the period of the borrowings using the effective interest method.

Fees paid on the establishment of loan facilities are recognized as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. If so, the fee is deferred until the draw-down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalized as a pre-payment for liquidity services and amortized over the period of the facility to which it relates.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

Deferred Revenue

Deferred revenue includes amounts related to installation, training, extended warranty, and post customer support contract associated with the sale of Novra's products. If the revenue recognition associated with these services is expected to take place within 12 months from the balance sheet date, we present the deferred revenue as current; otherwise the deferred revenue is presented as non-current.

Provisions

Novra provides a one-year manufacturer's warranty for its products at no additional cost to the customer. Estimates of future warranty costs are accrued at the time of product shipment and included in cost of revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss).

Management periodically reviews the provision for product warranty and records adjustments based on the terms of warranties provided to customers, historical and anticipated warranty claims experience, and estimates of the timing and cost of warranty claims. Factors that could impact the provision for product warranty include the success of our productivity and quality initiatives, as well as parts and labour costs. A higher degree of scrutiny is exercised in establishing product warranty provision related to sales of new products.

Convertible Note

Convertible note issued by Novra is known as a compound financial instrument as it can be converted to Novra's common shares at the option of the holder, and the number of common shares to be issued does not vary with changes in their fair value.

The liability component of a convertible note is recognized initially at the fair value of a similar liability that does not have an equity conversion option. The equity component is recognized initially at the difference between the fair value of the convertible note as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

After initial recognition, the liability component of a convertible note instrument is measured at amortized cost using the effective interest method. The equity component of a convertible note instrument is not re-measured subsequent to initial recognition except on conversion or expiry.

Revenue Recognition

Novra revenues consist of sales of satellite communications equipment and network products, product repair services, installation, training, extended warranty and post contract customer support.

Revenue is measured at fair value of the consideration received or receivable, and represents amounts receivable for goods supplied, stated net of discounts, returns, and sales / value added taxes. We recognized revenue when there is persuasive evidence of an agreement with the customer exits, delivery has occurred or services have been provided, the sales price is fixed or determinable, collectability is reasonably assured, and risk of loss and title have transferred to the customer.

Revenue recognition for the following type of stand-alone sales is as follows:

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

a) Sales of Products

Hardware products are typically sold on a stand-alone basis. Embedded in our hardware products is internally developed software of varying applications that function together with the hardware to deliver the product's essential functionality. The embedded software is not sold separately and we do not provide post-contract customer support specific to embedded software. The functionality that the software provides is marketed as part of the overall product and accordingly we do not record separately the revenue associated with the embedded software.

Revenue from hardware products is recognized when risk of loss and title has transferred which is generally upon shipment. For virtually all international shipments, customer contracts are fulfilled under shipping terms known as "Ex-Works", in accordance with international commercial terms. In these instances, revenue is recognized upon delivery, which is the date that the goods are made available to the customer as requested by the customer and no further obligations of Novra's remain. Where final acceptance of the hardware is required by the customer, revenue is deferred until acceptance criterion has been met. For instance, most delivery of headend solution to customers require customer acceptance and consequently the revenue is delayed until then.

For standalone software products, we recognize revenue upon releasing the perpetual software license to the customer.

Shipping and handling costs charged to customers are recorded as an offset in cost of revenue.

b) Sales of Services

We recognize revenue associated with product repairs, professional installation, and training services in the accounting period in which the services have been performed.

c) Sales of Extended Warranty

Revenue on extended warranty for Novra's products is initially deferred and recognized in income on a straight-line basis over the contract period. Extended warranty revenue is recognized only after Novra's one year manufacturer's warranty expires.

d) Sales of Post Contract Support

Revenue on post contract support is initially deferred and recognized in income on a straight-line basis over the contract period. Post contract customer support includes support levels that provides customers with access to telephone support for trouble-shooting, diagnosis and extends to on-site repair of products. Novra also provides software upgrades on a when and if available basis and software support for a fixed annual fee.

Occasionally, we enter multiple-element sales arrangements in which the sales transaction may bundle the hardware, multi-year extended warranty, new feature development and the associated post customer support contract. When arrangements contain multiple elements, the deliverables are separated into more than one unit of accounting when the following are met:

- the delivered item(s) has value to the customer on a stand-alone basis; and
- if a general right of return exists relative to the delivered item(s), the delivery or performance of an undelivered item is probable and substantially in Novra's control.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

We then allocate revenue to all deliverables based on their relative selling prices. In such circumstances, we use the following hierarchy to determine the selling price to be used for allocating revenue to deliverables:

- i) Vendor specific objective evidence ("VSOE") of selling price;
- ii) If no VSOE exists, third party evidence of selling price ("TPE") is used; or
- iii) If neither VSOE nor TPE exists, then management's best estimate of the selling price ("BESP").

VSOE generally exists only when we sell the deliverable separately and is the price we actually charged for that deliverable. The objective of the BESP is to determine the price at which we would transact a sale if the product or service were sold on a stand-alone basis. We determine BESP for a product or service by considering multiple factors including, but not limited to: geographies, market conditions, competitive landscape, internal costs, gross margin, and pricing practices. If a delivered item does not meet the criteria in the applicable accounting guidance to be considered a separate unit of accounting, revenue is deferred until the undelivered units are fulfilled. Accordingly, the determination of BESP can impact the timing of revenue recognition for an arrangement.

Research and Development Costs

Novra incurs research and development costs associated with the design of new technology. Expenditures during the research phase are expensed as incurred, net of associated investment tax credits (ITCs) realized. Expenditures during the development phase are capitalized if certain criteria, including technical feasibility and intent and ability to develop and use the technology, are met; otherwise they are expensed as incurred. Such capitalized costs are amortized over their expected useful lives. No amounts have been capitalized to date.

ITCs, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. The ITCs are presented net of the research and development expenses in the Consolidated Statements of Operations and Comprehensive Income (Loss).

Leases

Leases that transfer substantially all of the benefits and risks of ownership of the leased assets to Novra are capitalized by recording the present value of future minimum payments under the lease as a capital asset and a liability in the Consolidated Statements of Financial Position. Assets recorded under finance leases are amortized using the rates consistent with those used by the Corporation for similar assets.

For leases, which are classified as operating leases, lease payments are recognized as an expense on a straight-line basis over the lease term.

Page 18

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

Income taxes

Income taxes comprise current and deferred income taxes. Income taxes are recognized in the Consolidated Statements of Operations and Comprehensive Income (Loss), except to the extent that they relate to a business combination or items recognized in other comprehensive income (loss) or directly to equity.

1) Current income taxes

The taxes currently payable are based on the taxable income for the year, using tax rates enacted or substantively enacted at the balance sheet date in the countries where the Parent and its subsidiaries operate and generate taxable income. Additionally, it includes any adjustment to tax payable in respect of previous years. Taxable profit differs from IFRS profit because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible.

2) Deferred income taxes

Deferred income taxes are recognized using the asset and liability method. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax effects of temporary differences between financial reporting and taxable income (loss) and for tax credit and loss carryforwards. This is measured on a non-discounted basis using tax rates and laws that were enacted or substantively enacted at the dates of the Consolidated Statements of Financial Position and are expected to apply when the deferred income tax asset or liability is settled. We establish a valuation allowance when it is more likely than not that future taxable profits will not be sufficient to allow all or part of the deferred tax assets to be utilized.

Recognition of deferred tax assets for unused tax losses, tax credits and deductible temporary differences is restricted to those instances where it is probable that future taxable profit will be available against which the deferred tax asset can be utilized. At the end of each reporting period, management reassess unrecognized deferred tax assets. We recognize a previously unrecognized deferred tax asset to the extent that it has become probable that future tax profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are presented as non-current.

Employee Benefits

a) Pension obligations

Novra offers a Group Registered Savings Plan (Group RSP) to employees. This is a contribution pension plan under which Novra makes fixed contributions to Group RSP, subject to a minimum contribution by the employee. Novra has no legal or constructive obligations to pay further contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to the employee service in the current and prior periods. Pension contribution costs are recognized at the time employees make contributions to the Group RSP.

b) Termination benefits

We recognize termination benefits when Novra has demonstrably committed to either terminating the employment of current employees according to a detailed formal plan without possibility of

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

withdrawal, or providing benefits as a result of an offer made to encourage voluntary termination. Benefits falling due more than 12 months after the end of the reporting period are discounted to their present value.

Share-based compensation

Novra has a stock option plan for directors, executives, employees, and consultants. Grants are subject to a service condition by the option holder.

All option grants are initially measured at fair value using the Black-Scholes option pricing model. The fair value of the options is amortized over the vesting period and is included in operating expenses with a corresponding increase in contributed surplus, net of an estimated forfeiture credit. Management reassess the estimated forfeiture credit at each reporting period. Where the terms and conditions of the initial option grant are modified before they vest, the options are remeasured at fair value at the modification date and any increase in fair value is charged to earnings.

When options are exercised, common shares are issued from treasury and the proceeds are credited to share capital in the Consolidated Statements of Financial Position.

Share Capital

Common shares, options and warrants issued by Novra are classified as equity. Incremental costs directly attributable to the issue of these financial instruments are shown in equity as a deduction, net of tax, from the proceeds.

Recently Issued Accounting Standards Not Yet Adopted

IFRS 15 Revenue from Contracts with Customers

In April 2014, the IASB released IFRS 15, Revenue from Contracts with Customers, ("IFRS 15"), which replaces IAS 11, Construction Contracts and IAS 18, Revenue. This new standard specifies how and when companies will recognize revenue as well as requiring such entities to provide users of financial information with more informative, relevant disclosures. The standard provides a single, principles based five-step model to be applied to all contracts with customers. IFRS 15 applies to annual reporting periods beginning on or after January 1, 2018. We have not yet assessed the impact of the adoption of this standard on Novra's Consolidated Financial Statements.

IFRS 9 Financial Instruments

In July 2014, the IASB issued the final version of IFRS 9, *Financial Instruments*, bringing together the classification and measurement, impairment and hedge accounting phases of the project to replace IAS 39, *Financial Instruments: Recognition and Measurement*. This standard simplifies the classification of a financial asset as either at amortized cost or at fair value as opposed to the multiple classifications which were permitted under IAS 39. The classification under IFRS 9 is based on how an entity manages its financial instruments in the context of its business model and the contractual cash flow characteristics of the financial assets. This standard also requires the use of a single impairment method as opposed to the multiple methods in IAS 39. IFRS 9 is to be applied retrospectively for annual reporting periods beginning on or after January 1, 2018. Early application is permitted. We have not yet assessed the impact of the adoption of this standard on Novra's Consolidated Financial Statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

IFRS 16 Leases

In January 2016, the IASB issued IFRS 16, Leases, which replaces IAS 17, Leases. The standard provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. The new lease standard continues to require lessors to classify leases as operating or finance. IFRS 16 is to be applied retrospectively for annual periods beginning on or after January 1, 2019. Earlier application is permitted if IFRS 15 has also been applied. We have not yet assessed the impact of the adoption of this standard on Novra's Consolidated Financial Statements.

3. Critical Accounting Estimates and Judgments

The preparation of our Consolidated Financial Statements and related disclosures requires us to make estimates and assumptions about future events that can have a material impact on the amounts reported in our Consolidated Financial Statements and accompanying notes. Consequently, actual results could differ from those estimated. Our significant accounting policies are described in Note 2. The following critical accounting policies are those that we believe require a high level of subjectivity and judgment and have a material impact on Novra's financial condition and operating performance.

1) Revenue Recognition

Our sales arrangements occasionally involve multiple elements, including hardware, installation and professional services, extended product warranty, post-contract technical support. We allocate revenue to all of these deliverables using the relative selling price hierarchy (see Note 2). Where VSOE of selling price does not exist for an element, we are required to then look to third-party evidence of selling price. However, third-party evidence is generally not available as our product offerings differ from those of our competitors and competitor pricing is often not available. As a result, we generally use the BESP to estimate the selling price for an element which is subject to significant management judgement.

2) Inventory Obsolescence

We exercise significant judgment to estimate a provision for obsolete and slow-moving inventory. The inventory valuation process includes a review of future demand for Novra's products based on current sales pipeline; the stage of the product life cycle of Novra's product; customer acceptance; ability to repurpose slow-moving finished goods into other products showing greater market interest; and an assessment of the selling price in relation to the product cost. If our demand forecast for specific products is greater than actual demand and we fail to reduce manufacturing output accordingly, Novra could be required to write off inventory, which could negatively impact Nova's gross profit.

During 2016, Novra incurred an impairment charge of \$81 thousand (2015 - \$19 thousand) due to obsolete and slow-moving inventories.

3) Fair value of Wegener Options

As disclosed in Note 9, Novra received 15 million stock options to purchase Wegener common shares at \$0.03 USD each ("Wegener options"). Wegener's common stock is not liquid and trades on the Over the Counter (OTC) Markets in the United States. We have used the Black-Scholes option pricing model to estimate the fair value of Wegener options, which incorporates the stock price of Wegener as published by the OTC Markets as well as the associated trading volatility. Due to the lack of active

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

trading and liquidity in Wegener's common stock, a third party may determine a significantly different fair value for the Wegener options.

4) Business Combination

The acquisition of IDC was accounted for by the acquisition method (see Note 4). Under this method, assets acquired and liabilities assumed as part of the business combination are recorded at their fair value at the date of acquisition. The excess of purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill.

The determination of fair value of identifiable assets and liabilities assumed required significant management judgement and estimate due to limited comparable observable market data, particularly for the following:

a) Inventories - finished goods

Fair value was based on estimated selling price less the sum of a) cost of disposal and b) a reasonable profit allowance for our selling effort.

b) Equipment

Fair value was based on estimated resell value observed in the secondary market for comparable used equipment, where available. Where limited or no information was available, management reviewed the remaining net book value on a pooled asset basis and concluded it approximated fair value.

c) Deferred revenue

Fair value was based on the carrying value less a reasonable profit margin that a third party would require to service the support contracts and the extended product warranty program.

d) Provision

Fair value was based on the carrying value less a reasonable profit margin that a third party would require to service the product warranty program.

Additionally, the identification and fair value measurement of IDC's intangible assets required significant management judgment.

5) Impairment of Non-Financial Assets

On June 15, 2016, Novra recorded \$940 thousand of intangible assets in connection with the acquisition of IDC. At December 31, 2016, the market capitalization of Novra's common stock listed on the TSX-V was \$3.3 million or \$2.5 million greater than the carrying value of Novra's net assets on this same date. Further, IDC was profitable for the period post-acquisition in 2016 and the business fundamentals remain positive for the next twelve months. Accordingly, management has concluded there was no impairment on the intangible assets at December 31, 2016.

6) Product Warranty

At December 31, 2016, Novra's product warranty provision was \$56 thousand (2015 - \$nil). We provide a one-year product warranty at no additional cost to the customer. Estimates of future warranty costs are accrued at the time of product shipment and included in cost of revenues in the Consolidated Statements of Operations and Comprehensive Income (Loss).

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

For 2016, product warranty claims varied from 1% to 2% of trailing twelve month revenues for Novra's product lines. Management periodically reviews the provision for product warranty and records adjustments based on the terms of warranties provided to customers, historical and anticipated warranty claims experience, and estimates of the timing and cost of warranty claims. Factors that could impact the provision for product warranty include the success of our productivity and quality initiatives, as well as parts and labour costs. A higher degree of scrutiny is exercised in establishing product warranty provision related to sales of new products.

4. Acquisition of International Datacasting Corporation

On June 15, 2016, Novra completed the merger (acquisition) transaction with IDC. Management believes this Merger will enable Novra to further diversify its revenue base with complimentary products, become a dominant global media broadcast technology provider, and position itself well for the pending infrastructure renewal within the industry with new and cost effective solutions.

a) Consideration Transferred

Under the terms of the Merger, Novra acquired 100% of the issued and outstanding common shares of IDC for total purchase consideration of \$1.9 million.

The following table summarizes the acquisition-date fair value of each major class of consideration transferred.

Cash	\$ 669
6,689,342 of Novra common shares	736
13,336,145 of Novra warrants	455
Total consideration transferred	\$ 1,860

The fair value of the Novra common shares was based on Novra's closing stock price on June 15, 2016. For estimating the fair value of Novra's warrants, we used the Black-Scholes valuation model (see Note 16(b)).

The net cash outflow as at the closing of the merger was as follows:

Consideration paid in cash	\$ 669
Less: cash balances acquired	(618)
Net cash outflow on acquisition	\$ 51

The cash consideration was financed through an unsecured promissory note received from a related party on June 9, 2016 (see Note 23(d)).

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

b) Identifiable Assets Acquired and Liabilities Assumed

The following identifiable assets and liabilities were subject to management's best estimates and assumptions after taking into consideration all relevant information available. The purchase price allocation to the net assets acquired was as follows:

Net assets acquired:	
Cash	\$ 618
Trade and other receivables	243
Inventories	907
Notes receivable	118
Current taxes recoverable	4
Prepayments	116
Equipment	143
Intangible assets	940
Amounts payable and accrued liabilities	(284)
Customer deposits	(126)
Deferred revenue	(766)
Provisions	(53)
Total net assets acquired	\$ 1,860

c) Intangible Assets

Intangible assets of \$940 thousand relate to assumed technology assets and will be amortized on a straight-line basis over their estimated useful lives of three years.

There was no assumed goodwill on this acquisition as the entire purchase consideration was allocated to identifiable and intangible net assets.

d) Acquisition-related Costs

Novra has incurred costs totaling \$158 thousand related to the acquisition of IDC. These costs were recorded in general and administrative expenses during 2016, with the exception of \$15 thousand associated with the issuance of common stock and warrants which were reflected net of the equity proceeds.

e) Impact of IDC's Results to Novra

For the post-acquisition period in 2016, IDC contributed revenue of \$3.6 million and \$339 thousand in net income to Novra's consolidated results. If the acquisition had occurred on January 1, 2016, management estimates that Novra's proforma consolidated revenue would have been \$6.9 million and net loss of \$1.8 million for 2016. In determining these amounts, management has assumed that the fair value adjustments that arose on the date of acquisition would have been the same if the acquisition had occurred on January 1, 2016.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

5. Financial Risk and Capital Management

Financial Risk Management Objectives and Policies

In the normal course of business, we are exposed to a variety of financial risks: market risk (including foreign exchange risk, fair value interest rate risk, cash flow interest rate risk and price risk), liquidity risk and credit risk of non-performance by counter parties. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring procedures. From time to time, we may use derivative financial instruments to hedge certain risk exposures.

Financial risk factors

a) Market risk

Market risk is the risk that changes in market prices will affect Novra's earnings or the value of its holdings of financial instruments.

i) Foreign exchange risk

Foreign exchange risk is the risk to Novra's earnings that arise from fluctuations of foreign exchange rates and the degree of volatility of those rates.

We operate internationally and therefore we are exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the U.S. dollar and Euro. Foreign exchange risk arises from future commercial transactions, recognized assets and liabilities and net investments in foreign operations.

We do not currently have a formal hedging program to mitigate Novra's exposure to foreign currency risk; however, management may speculate on the foreign currency trend and enter into derivative financial instruments. Unrealized gains or losses on outstanding foreign currency derivative contracts (e.g. futures, forwards, swaps) are reflected in the Consolidated Statements of Operations and Comprehensive Income (Loss) based on currency rates as at the date of the Statements of Consolidated Financial Position.

At December 31, 2016 and 2015, we had no outstanding foreign currency derivative contracts.

At December 31, 2016, if the Canadian dollar had weakened/strengthened by 5% against the U.S. dollar and Euro with all other variables held constant, the resulting change to Novra's consolidated net loss would have been \$91 thousand lower/higher.

ii) Cash flow interest rate risk

Interest rate risk is the risk that the value of a financial instrument, and consequently net income, might be adversely affected by a change in the interest rates.

Borrowings issued at variable interest rates expose Novra to cash flow interest rate risk. Novra's RBC Credit Facilities (see Note 12) and the \$400 thousand USD unsecured promissory note due to IMT (see Note 23) are subject to variable interest rates. In 2016, we have not entered into interest rate swaps to mitigate this cash flow interest rate risk.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

An increase of 1% in the floating interest rate with all other variables held constant, would result in an increase of \$26 thousand in interest expense for the year.

iii) Price risk

Novra has market risk attributable to its holdings in Wegener options as detailed in Note 9.

At December 31, 2016, if the underlying Wegener common stock (traded over the counter in the United States) had increased/decreased by 5% with all other variables held constant, the resulting change to Novra's consolidated net loss would have been insignificant.

b) Liquidity risk

Liquidity risk is the risk that we will not be able to meet our financial obligations as they come due. Management monitors continuously both actual and forecasted cash flows to ensure Novra has sufficient liquidity to meet operational needs while maintaining sufficient headroom on its undrawn RBC Credit Facilities (see Note 12) at all times so that Novra does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities.

The following tables analyzes Novra's financial liabilities, including commitments, based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

			Within		1 to		3 to
Payment due:	Total	otal 1 year		3 years		;	5 years
Bank borrowings	\$ 2,130	\$	2,130	\$	-	\$	-
Operating leases	650		304		346		-
Trade payables and other payables	634		634		-		-
Loan payable to Crocus	377		104		273		-
Purchase commitments	498		477		13		8
Repayable government contribution	64		-		64		-
Total third party contractual obligations	4,353		3,649		696		8
Promissory notes from related party	1,172		531		494		147
Advances from related parties	371		371		-		-
Convertible note from related party	285		-		285		-
Total contractual obligations	\$ 6,181	\$	4,551	\$	1,475	\$	155

At December 31, 2016, Novra's financial assets of \$4.9 million were adequate to meet all third party contractual obligations due within the next 12 months. Accordingly, management believes Novra has adequate liquidity and working capital to meet its financial liabilities for the next 12 months.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

c) Credit risk

Credit risk arises from the potential that a counter party will fail to perform its obligations.

Novra's credit risk is primarily attributable to its cash holdings, accounts receivable and notes receivable. We do not use credit derivatives or similar financial instruments to mitigate Novra's credit risk. However, as part of our overall credit risk management, we may buy credit insurance from Export Development Canada (EDC) and seek customer deposits to mitigate credit risk in foreign markets. Novra's maximum credit risk exposure at December 31st was as follows:

	2016	2015
Cash	\$ 1,265	\$ 577
Restricted non-redeemable GIC	200	200
Trade receivables	2,727	816
Notes receivable	134	138
	\$ 4,326	\$ 1,731

To further mitigate credit risk our cash and derivative financial instruments are held by highly reputable, large financial institutions.

Trade and other receivables

The trade and other receivables includes the following at December 31st:

	2016	2015	
Trade accounts receivable	\$ 2,756	\$	816
Less: allowance for doubtful accounts	(29)		-
Net trade accounts receivable	2,727		816
Tax credits and grants receivable	12		-
VAT/HST and other receivables	65		29
Total trade and other receivables	\$ 2,804	\$	845

The following table shows the aging of trade receivables that were not impaired at December 31st:

	2016	2015
Current	\$ 2,262	\$ 502
Past due: Less than 30 days	13	8
31-60	12	5
61-90	212	280
Greater than 90 days	228	21
	\$ 2,727	\$ 816

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

At December 31, 2016, three customers accounted for 80% of the total trade receivables, one of them being Wegener with 22% (see Note 9). At December 31, 2015, one customer (Wegener) accounted for 86%. To mitigate our credit risk exposure with Wegener, we have obtained from Wegener's secured lender a financial guarantee of up to \$350 thousand USD in excess of the first \$150 thousand USD financial loss, in the event Wegener defaults on their payment to Novra. Further, the consideration payable on the 15 million Wegener options, if exercised, may be settled as an offset to the amount owed to Novra.

The large balance due over 60 days included \$429 thousand due from Wegener, which we have fully collected in February 2017.

The movements in Novra's allowance for doubtful accounts were as follows:

	2016		:	2015
Start of the year	\$	-	\$	67
Provision for impairment		29		8
Receivables written off during the year as uncollectable		-		(75)
Provision reversed due to subsequent collections		-		
End of year	\$	29	\$	-

Notes receivable

Refer to Note 7 for further details. Management believes there was no impairment on the outstanding note receivable at December 31, 2016.

Capital Management

Our key objectives when managing capital are to maintain a strong capital base in order to:

- maintain investor, creditor and market confidence;
- advance Novra's corporate strategies to generate attractive risk-adjusted return over the longterm for our shareholders;
- sustain Novra's operations and growth through all cycles; and
- ensure compliance with the covenants of any applicable credit facility and other financing facilities.

Management monitors Novra's capital and capital structure on an ongoing basis to ensure it is sufficient to achieve Novra's short-term and long-term objectives.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

Our capital resources consisted of the following at December 31st:

	2016	2015
Bank borrowings (drawn)	\$ 2,130	\$ 555
Promissory notes from related party	1,172	253
Convertible note from related party	285	-
Loan payable - Crocus	377	477
Repayable government contribution	64	-
Shareholders' equity	806	408
Total capital resources	\$ 4,834	\$ 1,693

6. Inventories

The breakdown of inventories was as follows at December 31st:

	2016	2015	
Finished goods	\$ 1,310	\$	2
Raw materials	2,127		471
Work-in-progress	43		58
Provision	(1,321)		-
	\$ 2,159	\$	531

The cost of inventories charged to cost of sales in 2016 was \$2.3 million (2015 - \$1.5 million), including an impairment charge for slow-moving and obsolete inventory of \$81 thousand in 2016 (2015 - \$19 thousand).

7. Notes Receivable

During 2014, we entered an unsecured promissory note of \$100 thousand USD with Wegener Communications Inc. (see Note 8). This note was originally due on September 23, 2015 and was subsequently extended to February 26, 2016, June 30, 2016, and December 31, 2016. The promissory note is unsecured and bears interest at 4% per annum. At December 31, 2016, the unsecured promissory note plus accrued interest remained outstanding. On January 1, 2017, we agreed to further extend the maturity date to June 30, 2017.

As part of the IDC acquisition (see Note 4), we had a note receivable of \$118 thousand due from a third party in connection with an asset sale. This note was fully collected in 2016.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

8. Financial Instruments

The following tables present the carrying amount and fair value of financial assets and liabilities, including their levels in the fair value hierarchy.

			Carrying Am	ount			Fair Value						
		Othe	er financial	Assets	/ Liabilities								
	Loans and		s/liabilities		ir value								
At December 31, 2016	receivables	at am	ortized cost	throug	h earnings	Total	Lev	vel 1	Level 2	Level 3		Total	
Financial assets measured at fair value:													
Derivative financial instrument	\$ -	\$	-	\$	32	\$ 32	\$	-	\$ 32	\$ -	\$	32	
Financial assets not measured at fair value:													
Current financial assets:													
Cash	\$ 1,265	\$	-	\$	-	\$ 1,265					\$	1,265	
Restricted non-redeemable GIC	200		-		-	200						200	
Trade and other receivables	2,804		-		-	2,804						2,804	
Notes receivable	134		-		-	134						134	
Prepayments(deposits only)	472					472						472	
Current tax receivable	4		-		-	4						4	
Total current financial assets	4,879		-		32	4,911						4,879	
Non-current financial assets:	-		-		-	-						-	
Total financial assets	\$ 4,879	\$	-	' \$	32	\$ 4,911					\$	4,911	
Financial liabilities not measured at fair value:													
Current financial liabilities:													
Trade and other payables	\$ -	\$	634	\$	-	\$ 634					\$	634	
Borrowings	-		2,130		-	2,130						2,130	
Loan payable	-		104		-	104						104	
Customer deposits	-		119		-	119						119	
Advances from related parties	-		371		-	371						371	
Promissory notes from related party	-		531		-	531						531	
Total current financial liabilities	-		3,889		-	3,889						3,889	
Non-current financial liabilities:													
Loan payable	-		273		-	273						273	
Promissory notes from related party	-		641		-	641						558	
Convertible note	-		285		-	285						285	
Repayable government contribution	-		64		-	64						58	
Total non-current financial liabilities	-		1,263		-	1,263						1,174	
Total financial liabilities	\$ -	\$	5,152	\$	-	\$ 5,152					\$	5,063	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

			Carrying A	mount			Fair Value							
At December 31, 2015	oans and ceivables	liab	r financial ilities at tized cost	at fair va	/ Liabilities alue through ofit and loss	Total	Le	vel 1	Lev	rel 2	Lev	el 3	1	Fotal
Financial assets measured at fair value:				-										
Derivative financial instrument	\$ -	\$	-	\$	55	\$ 55	\$	-	\$	55	\$	-	\$	55
Financial assets not measured at fair value:														
Current financial assets:														
Cash	\$ 577	\$	-	\$	-	\$ 577							\$	577
Trade and other receivables	845		-		-	845								845
Note receivable	138		-		-	138								138
Total current financial assets	1,560		-		-	1,560								1,560
Non-current financial assets:														
Restricted non-redeemable GIC	200		-		-	200								200
Total financial assets	\$ 1,760	\$	-	\$	55	\$ 1,815							\$	1,815
Financial liabilities not measured at fair value:														
Current financial liabilities:														
Trade and other payables	\$ -	\$	27	\$	-	\$ 27							\$	27
Borrowings	-		555		-	555								555
Loan payable	-		100		-	100								100
Advances from related parties	-		387		-	387								387
Promissory notes from related party	-		253		-	253								253
Total non-current financial liabilites	-		1,322		-	1,322								1,322
Non-current financial liabilities:														
Loan payable	-		377		-	377								377
Total financial liabilities	\$ -	\$	1,699	\$	-	\$ 1,699								1,699

Financial instruments measured at fair value

We estimated the fair value of Novra's derivative financial instrument by using the Black-Scholes Option Pricing model. Refer to Note 9 for significant inputs used in this valuation model. Due to the use of significant observable market inputs in this valuation model, the fair value of the Wegener options is classified as Level 2 within the fair value measurement hierarchy.

Financial instruments not measured at fair value

The carrying amounts of trade and other receivables, note receivable, trade and other payables, borrowings, and advances from related parties approximate fair values because of the short-term nature of these financial instruments.

The following are valuation techniques we used to estimate the fair value of financial instruments with maturities longer than 12 months:

- Loan payable: We used the discounted cash flow model to estimate its fair value. We believe the 7.5% annual interest rate on the Crocus Loan approximates the market yield for a comparable secured loan based on our observation of the current borrowing cost under the RBC credit facilities in 2016 (see Note 12), adjusted for an additional spread to reflect the duration risk. Accordingly, the estimated fair value of the loan payable approximates its carrying value.
- Unsecured promissory note with related party: We used the discounted cash flow model to estimate its fair value. We applied a discount rate of 10%, which reflects the estimated market yield for a high yield bond index fund at December 31, 2016.
- Convertible note: This financial instrument was issued on December 1, 2016 (see Note 23), and was initially recorded at fair value based on the use of a discounted cash flow model, with the discount rate based on the market yield for a high yield bond index fund. There was no

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

significant change in the market yield for the same high yield bond index fund at December 31, 2016 and therefore the estimated fair value of the convertible note approximates its carrying value.

Repayable government contribution payable: This government contribution loan is unsecured. We used the discounted cash flow model to estimate its fair value and a 10% discount rate, consistent with the discount rate used for the unsecured promissory note.

9. Derivative Financial Instrument

On September 16, 2013, we entered a strategic agreement with Wegener Corporation ("Wegener"), a publicly traded US based communications technology company, in which we agreed to acquire Wegener subject to due diligence and restructuring.

As part this strategic agreement, we agreed to become a low margin supplier to Wegener's subsidiary, Wegener Communications Inc., in return for receiving 15 million stock options to purchase Wegener common shares at \$0.03 USD each ("Wegener options"), for a total consideration of \$450 thousand USD. This stock option agreement was set to expire on September 30, 2014 but was subsequently extended to December 31, 2015, June 30, 2016, and December 31, 2016. The Wegener options were initially valued at \$257 thousand, using the Black-Scholes option pricing model. These options are revalued at each reporting date, with the change reported as unrealized loss on options in Novra's Consolidated Statements of Operations and Comprehensive Income (Loss).

On December 31, 2016, Wegener has further extended the expiration date of the 15 million options to March 31, 2018. We have remeasured the estimated fair value for these extended Wegener options using the following key inputs in the Black Scholes option pricing model:

	December 31,	December 31,
	2016	2015
Expected life, in years	1.25	0.5
Volatility	122%	200%
Risk free interest rate	0.85%	0.48%
Dividend yield	0%	0%
Closing stock price at grant date	0.008	0.010

Accordingly, the estimated fair value of the Wegener options was \$0.0002 each for a total of \$32 thousand (2015: \$0.0037 each for a total of \$55 thousand) at December 31, 2016. Wegener had 13,147,051 common shares outstanding at December 31, 2016 and 2015.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

10. Equipment

	N	lachinery and						
		testing		Computer	Fur	niture and		
		equipment		equipment		fixtures		Total
Cost								
Opening balance at January 1, 2016	\$	248	\$	102	\$	35	\$	385
Additions		73		-		-		73
Acquired from IDC (see Note 4)		116		17		10		143
Disposals		(94)		(88)		(15)		(197)
Closing balance at December 31, 2016	\$	343	\$	31	\$	30	\$	404
Accumulated Amortization								
Opening balance at January 1, 2016	\$	231	\$	95	\$	33	\$	359
Amortization for the year		19		6		2		27
Disposals		(84)		(87)		(14)		(185)
Closing balance at December 31, 2016	\$	166	\$	14	\$	21	\$	201
Net Book Value at December 31, 2016	\$	177	Ś	17	\$	9	Ś	203

11. Intangible Assets

	Technology Assets
Cost	
Opening balance at January 1, 2016	\$ -
Acquired from IDC (see Note 4)	940
Closing balance at December 31, 2016	\$ 940
Accumulated Amortization	
Opening balance at January 1, 2016	\$ -
Amortization for the year	170
Closing balance at December 31, 2016	\$ 170
Net Book Value at December 31, 2016	\$ 770

12. Borrowings

On March 13, 2014, we entered into credit facilities with the Royal Bank of Canada ("RBC Credit

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

Facilities"), which were further amended in September 2016.

The following is a summary of the key terms and conditions of the RBC Credit Facilities:

a) Revolving Demand Facility

A revolving demand facility up to \$350 thousand, which is margined based on 75% of unencumbered accounts receivable that are less than 90 days outstanding, excluding inter-company receivables, plus 50% of unencumbered inventories up to a maximum of \$150 thousand. The interest rate under this facility is prime plus 0.5% per annum. At December 31, 2016, we have drawn \$300 thousand (December 31, 2015: \$60 thousand) from this credit facility, inclusive of accrued interest. During the first quarter of 2017, we fully repaid this facility.

b) Pre-Shipment Financing

- i) A revolving demand facility up to \$495 thousand to finance eligible pre-shipment costs in relation to multiple export contracts as insured by EDC. The interest rate on this facility is prime plus 0.75% per annum. At December 31, 2016, we have drawn \$368 thousand (December 31, 2015: \$495 thousand) from this credit facility, inclusive of accrued interest. During the first quarter of 2017, we fully repaid this facility
- ii) In 2016, the RBC Credit Facilities were amended to include a new non-revolving term facility up to \$1.45 million USD to finance 90% of eligible pre-shipment costs in connection with a large radio network contract awarded to Novra in July 2016. The interest rate under this facility is U.S. prime plus 1.05% and the borrowings are repayable in full on or before April 30, 2017, subject to repayments equal to any advance or partial repayment received from our customer. At December 31, 2016, we have drawn \$1.09 million USD from this credit facility, inclusive of accrued interest. During the first quarter of 2017, we fully repaid and terminated this facility.

c) Credit Card

We also have corporate Visa credit cards available for use up to a maximum limit of \$41 thousand in Canadian currency and US currency. At December 31, 2016, our Visa credit card liability was nil.

d) Foreign Exchange Forward Contracts

We may also enter foreign exchange forward contracts with RBC, up to a predetermined notional amount which varies based on the use of the above credit facilities.

The RBC Credit Facilities are repayable on demand and are secured by a General Security Agreement with RBC, providing a first ranking security in all personal property of Novra; however, the RBC Credit Facilities are subordinated to the security provided under the loan payable (see Note 14). Further, we have entered a cash collateral agreement in which we assigned \$200 thousand non-redeemable GIC in favor of RBC.

13. Provisions

We provide a one-year manufacturer's warranty for Novra's products at no additional cost to the customer. The following table shows the movement in the warranty provision in 2016.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

At January 1, 2016	\$ -
Assumption of IDC's product warranty provision (see Note 4)	53
Additional provision	20
Payments during the year	(17)
At December 31, 2016	\$ 56

Product warranty costs were negligible in 2015.

14. Loan Payable

On January 15, 2004, we entered a \$750 thousand loan agreement with Crocus Investment Fund ("Crocus Loan"). On September 1, 2011, the terms of the Crocus Loan were renegotiated and all accrued interest to the date of the amended agreement was forgiven. The new terms of the Crocus Loan call for interest at 7.50% per annum and a blended annual repayment of \$120 thousand, maturing on September 1, 2020. Factoring in all interest free periods and expected repayment amounts, the effective interest rate on the amended loan agreement is 4.47%. The carrying value of the Crocus Loan is calculated based on this effective rate. The Crocus Loan is secured by all the personal property of Novra.

The following table provides a breakdown of the loan payable as presented in the Consolidated Statements of Financial Position at December 31st:

	2016	2015
Crocus Ioan	\$ 377	\$ 477
less: Current portion	(104)	(100)
Non-current portion	\$ 273	\$ 377

Principal repayment terms are as follows:

2017	\$ 104
2018	109
2019	114
2020	50
	\$ 377

15. Repayable Government Contribution

On June 5, 2015, Novra entered a contribution agreement with Western Economic Diversification Canada ("WEDC"), which was further amended on October 19, 2016. Under this agreement, Novra is eligible to receive a repayable contribution not exceeding \$447.5 thousand towards the commercialization of two new innovative technology-based products. Under the agreement, Novra shall repay the contributions by 59 consecutive monthly installments of \$7.4 thousand and one final installment of \$10.9 thousand commencing April 1, 2018 and ending March 1, 2023, when any principal and interest then outstanding shall be repaid. The contributions are subject to interest at the

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

average bank rate plus 3% if any payments are late. See Note 26(a) for a further amendment to the contribution agreement subsequent to the reporting period.

In 2016, we received \$64 thousand of repayable contributions, which remains outstanding at December 31, 2016.

16. Shareholders' Equity

a) Common Stock

The following table provides a summary of authorized as well as issued and outstanding capital for Novra at December 31st:

		2016	2	015
Authorized:				
Unlimited	Class "A" Common voting shares			
Unlimited	Class "B" Common non-voting shares			
Unlimited	Class "C" Preferred shares,			
	redeemable and retractable at \$1,000			
Issued:				
29,077,435 (20	15: 22,387,993)			
Class "A" con	nmon voting shares	\$ 6,778	\$	6,057

On June 15, 2016, 6,689,342 voting common shares with a value of \$721 thousand were issued as part of the merger with IDC, net of \$15 thousand of related issuance costs (see Note 4). During the year ended December 31, 2015, there was no change to Novra's issued share capital.

b) Warrants

On June 15, 2016, 13,336,145 warrants with a value of \$455 thousand were issued as part of the merger with IDC (see Note 4) and are reported under contributed surplus in the Consolidated Statements of Changes in Shareholders' Equity. The warrants provide the right to purchase one common share at \$0.12 each and expire on June 15, 2017, one year after their issuance on June 15, 2016. The warrants were valued on the issuance date using the Black-Scholes pricing model based on the following key inputs:

Expected life	1 year
Volatility	86%
Risk free interest rate	0.59%
Dividend yield	Nil
Closing stock price	\$0.11
Exercise price of warrant	\$0.12

There were 100 warrants exercised in 2016.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

c) Stock Options

At December 31, 2016 and 2015, we had no outstanding stock options (see Note 26(b)).

17. Earnings (Loss) Per Share ("EPS")

a) Basic EPS

Basic EPS is calculated by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the year.

	2016	2015
Net income (loss)	\$ (796)	\$ 361
Weighted average number of common shares	26,043	22,388
Basic EPS	\$ (0.03)	\$ 0.02

b) Diluted EPS

Diluted EPS is calculated by adjusting the weighted average number of common shares to assume conversion of all dilutive common shares.

We have two types of dilutive potential common shares at December 31, 2016: convertible note and warrants. The convertible note is assumed to have been converted into ordinary shares, and the net profit is adjusted to eliminate the interest expense less the tax effect. For warrants, a calculation is done to determine the number of common shares that could have been acquired at fair value (the average market price of Novra's common stock) based on the proceeds from exercise of warrants. The result of this calculation is then compared to the number of shares that would have been issued assuming the exercise of warrants. Convertible note and warrants would be both anti-dilutive when Novra incurs a net loss.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

		2016		2015
Earnings (Loss):				
	\$	(706)	\$	361
Net income (loss)	Ф	(796)	Φ	301
Interest expense on convertible note (net of tax) (1)		-		
Net income (loss) used to determine EPS	\$	(796)	\$	361
Weighted average number of common shares:				
Weighted average number of common shares		26,043		22,388
Adjustment for:				
- Assumed conversion of convertible note (1)		-		-
- Warrants (1)		-		-
Weighted average number of common shares				
for diluted EPS		26,043		22,388
Diluted EPS	\$	(0.03)	\$	0.02

⁽¹⁾ Convertible note and warrants were issued in 2016 and were anti-dilutive at December 31, 2016.

18. Research and Development Expense

The following table provides a summary of research and development ("R&D") costs incurred during the year, net of associated investment tax credits realized. The investment tax credits were provided by the Ontario Ministry of Finance to partially fund eligible R&D expenses (see Note 20(d)).

	2016	2015
R&D expenses	\$ 1,260	\$ 450
Investment tax credits	(4)	-
R&D expenses, net	\$ 1,256	\$ 450

19. Finance income and Finance Costs

a) Finance income

The following table provides a breakdown of total finance income.

	201	6	2015	
Interest income:				
- Restricted non-redeemable GIC	\$	2	\$	3
- Note receivable		5		4
	\$	7	\$	7

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

b) Finance costs

The following table provides a breakdown of total finance costs.

	2	016	2015
Interest expense:			
- Bank borrowings (see Note 12)	\$	49	\$ 46
- Unsecured promissory notes (see Note 23(d))		58	10
- Convertible note (see Note 23 (e))		3	-
Fees on bank borrowings and promissory notes		34	-
	\$	144	\$ 56

20. Income Taxes

a) Reconciliation of effective income tax rate

Novra's effective income tax rate differs from the statutory rate that would be obtained by applying the combined Canadian basic federal and provincial income tax rate to income (loss) before income taxes. These differences result from the following items:

	2016	2015
Income (loss) before income taxes	\$ (796)	\$ 361
Statutory income tax rate	27.0%	27.0%
Tax provision based on combined Canadian federal and provincial rates	(215)	97
Increase (decrease) resulting from:		
Origination and reversal of temporary differences	189	(2)
Non-deductible amounts and other permanent differences	41	12
Income tax rate difference	(3)	-
Utilization of tax credits	(107)	(68)
Other	95	(39)
Income tax recovery (expense)	\$ -	\$
Effective income tax rate	0.0%	0.0%

b) Investment Tax Credits

At December 31, 2016, Novra's federal and provincial investment tax credits ("ITCs") available to reduce future Canadian federal and provincial taxes payable were \$5.3 million and \$0.8 million respectively.

Page 39

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

The ITCs will expire as follows:

	F	Federal ITCs				rovincial ITCs	
2017	\$	_	\$	-			
2018		15		-			
2019		164		-			
2020		118		-			
2021 and after		4,994		821			
Total	\$	5,291	\$	821			

c) Loss Carry Forwards

In addition to the ITCs, Novra has accumulated a Scientific Research and Experimental Development ("SR&ED") expenditures pool that is available for an indefinite carry forward period with discretionary deductions of \$26.7 million.

Further, at December 31, 2016, Novra has approximately \$9.7 million of cumulative net operating losses that can be carried forward over 20 years, which will begin to expire in 2027.

d) Unrecognized net deferred tax assets

The tax effect of the temporary differences that give rise to unrecognized net deferred tax assets at December 31st are presented below:

	2016		2015
SR&ED pool	\$ 7,0	88 \$	-
Investment tax credits	4,73	33	-
Non-capital loss carry forwards	2,5	34	259
Net capital loss carry forwards	-		-
Eligible capital property	2	66	-
Capital assets	1	34	58
Other	(2)	27)	11
Unrecognized net deferred tax assets	\$ 14,6	18	328

We have not recognized the tax benefits associated with the unused tax losses, tax credits, and deductible temporary differences in the Consolidated Financial Statements as their ultimate realization are contingent on the generation of future taxable profits. Management concluded that this was not probable (minimum recognition threshold) based on the significant risks and uncertainties in projecting Novra's future taxable income and the lack of available income tax planning strategies.

21. Segmented Information

Following the merger with IDC in June 2016, Novra and its group of companies operate as one operating segment. While IDC will continue to operate independently in Ottawa, Canada, our Chief Operating Decision Maker (Novra's President and CEO) evaluates the company's operating performance and allocates resources based on information provided at a consolidated level.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

Based on the location of our customers, Novra's consolidated revenues by geographic market are as follows:

	2016	2015
Americas ex-Canada (1)	\$ 2,383	\$ 1,982
Canada	1,773	69
EMEA (2)	368	156
APAC (3)	518	506
	\$ 5,042	\$ 2,713

- (1) The geographic region of the Americas includes North America, Central America and South America.
- (2) EMEA consists of Europe, the Middle East and Africa.
- (3) APAC consists of East Asia, South Asia, Southeast Asia and Oceania.

For 2016, three customers accounted for more than 10% each of our total revenues, at a combined total of 48% (2015– three customers accounted for 85%).

In 2016 and 2015, Novra's equipment and intangible assets are all located in Canada.

22. Supplemental Cash Flow and Other Disclosures

The components of the net change in non-cash working capital at December 31st are as follows:

	2016	2015	
Trade and other receivables	\$ (1,716)	\$	(299)
Inventories	(801)		(102)
Notes receivable	122		(23)
Prepayments	(375)		128
Amounts payable including advances	998		137
Customer deposits	(7)		-
Deferred revenue	511		17
Provisions	3		
Total	\$ (1,265)	\$	(142)

Non-cash transactions in 2016:

- The issue of Novra's common shares and warrants as consideration for the acquisition of IDC (see Note 4).
- The transfer of \$181 thousand from amount payable to unsecured promissory note from IMT (see Note 23)
- The issue of \$300 thousand convertible note for the partial settlement of unsecured promissory note from IMT (see Note 23).

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

23. Related Party Transactions

The following is a summary of Novra's related party transactions:

a) Key management personnel compensation

On July 25, 2016, the Board of Directors appointed Patricia Gair to the newly defined role of Chief Operating Officer (COO). In this role, she oversees the internal operations of Novra and leads special strategic initiatives. Prior to this appointment, Ms. Gair was the Director of Operations & Chief Financial Officer (CFO) of Novra.

Additionally, on July 25, 2016, the Board of Directors appointed Steven Archambault as Novra's CFO while continuing to be the President and CFO of Novra's wholly-owned subsidiary, IDC. Mr. Archambault was previously the CFO and interim CEO of IDC.

The following table discloses the compensation of independent directors as well as key management personnel (President & CEO, COO, and CFO) in the ordinary course of their employment recognized as an expense during the year.

	2016	2015
Salaries and employee benefits	\$ 280	\$ 144
Directors' fees	8	8
	\$ 288	\$ 152

The 2016 key management personnel compensation includes Mr. Archambault's compensation only from June 16, 2016 to December 31, 2016, the post-acquisition period.

b) Transactions with other related parties

	2	016	2015
Sale of goods and services			
InfoMagnetics Technologies Inc.("IMT") (1)	\$	(6)	\$ -
Purchase of goods and services			
IMT		14	-
The Exchange Global Server Centre Inc. (2)		9	9
EXG Group Inc. (3)		-	11
Interest on unsecured promissory notes			
IMT		58	10
Interest on convertible note			
IMT		3	-
	\$	78	\$ 30

Novra's President & CEO has a controlling interest in IMT.

These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

The Exchange Global Server Centre Inc. is 50% owned by IMT.

Novra's Chairman of the Board was the Chairman of the EXG Group Inc. in 2015. He has since retired and as a result EXG Group Inc. is no longer a related party.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

c) The breakdown of advances from related parties by party at December 31st was as follows:

	2016	2015
Key management and directors (see part (a))	351	286
IMT	20	97
The Exchange Global Server Centre Inc.	-	3
EXG Group Inc.	-	1_
	\$ 371	\$ 387

At December 31, 2016, \$325 thousand (2015: \$268 thousand) was due to Novra's President & CEO in regards to unpaid salaries and expense reimbursements for current and prior years in which he voluntarily chose to not collect payment in the interest of preserving liquidity in the company. The payable amount bears no interest and has no repayment term.

d) The movement of unsecured promissory notes due to IMT was as follows:

	2016	2015
At January 1	\$ 253	\$ 252
Loans received	1,063	-
Transfer from advances	181	-
Partial settlement via convertible note (see part (d))	(300)	-
Loan repayments	(45)	-
Foreign exchange movement	(25)	-
Interest charged	58	10
Interest paid	(13)	(9)
At December 31	\$ 1,172	\$ 253
Presentation:		
Current portion	\$ 531	\$ 253
Non-current portion	641	-
Total	\$ 1,172	\$ 253

The following is a summary of loan transactions with IMT during 2016 and 2015.

- On November 5, 2014, Novra entered a \$250 thousand unsecured promissory note bearing 4% annual interest and maturing on August 31, 2015. The maturity date of this note was further extended to August 31, 2016 and December 1, 2016. On November 28, 2016, both parties agreed to further extend the maturity date to January 2, 2018 and maintain the fixed interest rate of 4% per annum. As of December 31, 2016, the remaining balance of the promissory note plus accrued interest was \$263 thousand (2015 \$253 thousand).
- On January 25, 2016, Novra entered a \$400 thousand USD unsecured promissory note bearing interest at the monthly USD floating base rate plus 2.5% per annum and maturing on November 1, 2022. The purpose of this note was to provide further liquidity to fund its working capital requirements. The USD floating base rate was 4.8% per annum at January

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

25, 2016 and 5.05% at December 31, 2016. As of December 31, 2016, the remaining balance of the promissory note plus accrued interest was \$382 thousand USD.

On June 9, 2016, Novra entered a \$681 thousand unsecured promissory, in exchange for receiving cash of \$500 thousand and a credit note of \$181 thousand against the amount payable to IMT. The cash proceeds were used to fund the acquisition of IDC (see Note 4). This note bears interest at 4% per annum and matured on December 1, 2016. As disclosed in part (d) of this note, \$300 thousand was settled as part of issuing a convertible note to IMT on December 1, 2016. Further, Novra and IMT have agreed to further extend the maturity date for the remaining balance to June 30, 2017 and maintain the fixed interest rate of 4% per annum. At December 31, 2016, the remaining balance of the unsecured promissory note plus accrued interest was \$395 thousand.

e) Convertible Note due to IMT:

	2016	2015	
Issuance of convertible note to IMT	\$ 300	\$	-
Amount reclassifed as equity	(18)		-
Accrued interest	3		-
Carrying value of convertible note	\$ 285	\$	-

On November 28, 2016, Novra's Board of Directors approved to enter a \$300 thousand unsecured convertible promissory note ("Convertible Note") with IMT effective December 1, 2016, as partial settlement of the \$681 thousand unsecured promissory note. Under this Convertible Note, IMT may at its sole discretion elect to partially or fully convert the debt to Novra's equity at a conversion rate of \$0.12 per Novra's common share. Such conversion may take place anytime after June 15, 2017 and if fully converted would result in the issuance of 2,500,000 common shares or 8.6% of total outstanding common shares at December 31, 2016. The Convertible Note bears a fixed interest rate of 4% per annum and matures on January 2, 2018.

In accordance with IFRS (see Note 2), we have recorded the estimated fair value of the equity component (i.e. call option feature) of the Convertible Note as part of contributed surplus in Novra's shareholders' equity, which amounted to \$18 thousand (see Note 8). At December 31, 2016, the carrying value of the Convertible Note, including accrued interest, was \$285 thousand.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

24. Operating Expenditures

We present our Consolidated Statements of Operations and Comprehensive Income (Loss) on a functional basis in which expenditures are aggregated to the function to which they relate. We have identified the major functions as general and administrative, sales and marketing, and research and development activities.

	General and	Sales and	Research and	_
2016	administrative	marketing	development	Total
Personnel expenditures	\$ 348	\$ 334	\$ 921	\$ 1,603
Other operating expenditures	568	256	150	974
Depreciation and amortization	1	2	185	188
	\$ 917	\$ 592	\$ 1,256	\$ 2,765

	General and	Sales and	Research and	
2015	administrative	marketing	development	Total
Personnel expenditures	\$ 69	\$ 25	\$ 369	\$ 463
Other operating expenditures	130	88	75	293
Depreciation and amortization	-	=	6	6
	\$ 199	\$ 113	\$ 450	\$ 762

25. Commitments and Contingent Liabilities

a) Lease commitments

Novra leases its head office location and is a co-tenant with IMT under the lease agreement. Monthly lease payments are made by IMT to the landlord and we reimburse IMT for our share of the rent. Following the acquisition of IDC, we entered a three-year lease agreement for its Ottawa office location.

At December 31, 2016, Novra's future minimum payments under non-cancellable operating leases are as follows:

2017	\$ 304
2018	233
2019	113
Total	\$ 650

b) Purchase Commitments

In the normal course of business, we may enter purchase commitments, including inventory and third party software license embedded in our products, to achieve economy of scale. At December 31, 2016, we had \$498 thousand of purchase commitments of which \$477 thousand is due within one year.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years ended December 31, 2016 and 2015

(Tabular amounts are in 000's, except share data)

26. Subsequent Events

a) Repayable Government Contributions

On February 23, 2017, the contribution agreement with WEDC was further amended to delay the repayment of the WEDC contributions by one year such that the 59 consecutive monthly installments of \$7.4 thousand and one final instalment of \$10.9 thousand shall commence on April 1, 2019 and end on March 1, 2024. Further the amount of funding by WEDC may not exceed the following amounts in WEDC's fiscal year ending March 31st:

Year	Amount
2016	\$64
2017	\$150
2018	\$233

On March 20, 2017, we submitted a contribution request of \$120 thousand to WEDC.

b) New Incentive Stock Option Plan

On April 28, 2017, the Board of Directors approved the 2017 Stock Option Plan ("2017 Plan") to retain and attract executives, directors and key employees. This replaces and terminates the current option plan. The 2017 Plan provides for the grant of stock options of up to an aggregate of 2,900,000 with a five-year vesting period and seven-year year term. The exercise price will be at least equal to the fair market value of Novra's common shares at the grant date as defined as the greater of:

- The volume weighted average trading price for Novra's common stock for the five market trading days immediately prior to the grant date; and
- The closing trading price of Novra's common stock on the day immediately prior to the grant date, net of the discounted market price (as defined by the TSX-V policy).

The Board has the discretion to amend general vesting provisions and the term of any award under the 2017 Plan, subject to the restrictions defined in the 2017 Plan.

On April 28, 2017, the Board of Directors approved the grant of 1,500,000 stock options to independent directors and employees under the terms of the 2017 Plan, subject to final approval by the TSX-V of the 2017 Plan. Once approved by the TSX-V, the exercise price will be set in accordance with the 2017 Plan, less 25% discount as permitted under the TSX-V rules and regulations; subject to a minimum of \$0.12. The vesting provision for this grant will be as follows:

```
20% on June 30, 2017;
20% on December 31, 2017;
20% on December 31, 2018;
20% on December 31, 2019; and
20% on December 31, 2020.
```